Eribulin was FDA approved in November 2010 based on results of the EMBRACE trial. This study showed women who took eribulin lived an average of 3 months longer than those who received a different chemotherapy of their doctor’s choice.
Eribulin works by blocking cancer cell growth by stopping mitosis, the process of cells dividing. It interferes with the growth phase of microtubules, the structures of the cell that help move information inside cells during mitosis.
- took an anthracycline and a taxane in the past, for either early-stage or metastatic disease
- have received at least two chemotherapy regimens for metastatic disease
Side effects may include:
- Low blood counts
- Hair loss
- Menopausal symptoms
Before starting eribulin, be sure to tell your doctor about any medicines you are taking, including vitamins, herbal supplements and over-the-counter medicines. Let your healthcare team know if you have heart or kidney problems.
You should avoid becoming pregnant while you are receiving eribulin. Tell your doctor right away if you become pregnant or may be pregnant while you are undergoing treatment.